200
M. Irfan et al.
References
1. Vogenberg FR, Barash CI, Pursel M (2010) Personalized medicine: part 1: evolution and
development into theranostics. Pharm Ther 35(10):560
2. Xing H, Hwang K, Li J, Torabi S-F, Lu Y (2014) DNA aptamer technology for personalized
medicine. Curr Opin Chem Eng 4:79–87
3. Tebani A, Abily-Donval L, Afonso C, Marret S, Bekri S (2016) Clinical metabolomics: the
new metabolic window for inborn errors of metabolism investigations in the post-genomic
era. Int J Mol Sci 17(7):1167
4. Wang T, Chen C, Larcher LM, Barrero RA, Veedu RN (2019) Three decades of nucleic acid
aptamer technologies: lessons learned, progress and opportunities on aptamer development.
Biotechnol Adv 37(1):28–50
5. Piffoux M, Nicolás-Boluda A, Mulens-Arias V, Richard S, Rahmi G, Gazeau F, Wilhelm
C, Silva AK (2019) Extracellular vesicles for personalized medicine: the input of physically
triggered production, loading and theranostic properties. Adv Drug Deliv Rev 138:247–258
6. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific
ligands. Nature 346 (6287):818–822
7. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA
ligands to bacteriophage T4 DNA polymerase. Science 249 (4968):505–510
8. Xing H, Wong NY, Xiang Y, Lu Y (2012) DNA aptamer functionalized nanomaterials for
intracellular analysis, cancer cell imaging and drug delivery. Curr Opin Chem Biol 16(3–
4):429
9. Beaudry AA, Joyce GF (1992) Directed evolution of an RNA enzyme. Science
257(5070):635–641
10. Willner I, Zayats M (2007) Electronic Aptamer-Based Sensors. AngewandteChemie International Edition 46(34):6408–6418
11. Cai S, Yan J, Xiong H, Liu Y, Peng D, Liu Z (2018) Investigations on the interface of nucleic
acid aptamers and binding targets. Analyst 143(22):5317–5338
12. Tao X, Huang Y, Wang C, Chen F, Yang L, Ling L, Che Z, Chen X (2020) Recent developments
in molecular docking technology applied in food science: a review. Int J Food Sci Technol
21(7):33–45
13. Yadav B, Sellamuthu B, Tyagi R (2020) Riboswitches and aptamers: potential future targets to
control drug-resistant bacteria. Current Developments in Biotechnology and Bioengineering:
Environmental and Health Impact of Hospital Wastewater, pp 421–462
14. Xiang D, Zheng C, Zhou S-F, Qiao S, Tran PH-L, Pu C, Li Y, Kong L, Kouzani AZ, Lin J
(2015) Superior performance of aptamer in tumor penetration over antibody: implication of
aptamer-based theranostics in solid tumors. Theranostics 5(10):1083
15. Urak KT (2018) Detection and treatment of critical illnesses using oligonucleotides
16. Wang RE, Wu H, Niu Y, Cai J (2011) Improving the stability of aptamers by chemical
modification. Curr Med Chem 18(27):4126–4138
17. Dunn MR, Jimenez RM, Chaput JC (2017) Analysis of aptamer discovery and technology.
Nat Rev Chem 1(10):1–16
18. Sun H, Zu Y (2015) A highlight of recent advances in aptamer technology and its application.
Molecules 20(7):11959–11980
19. Tan W, Li L, Xu S, Yan H, Li X, Yazd HS, Li X, Huang T, Cui C, Jiang J (2020) Nucleic acid
aptamers for molecular diagnostics and therapeutics: advances and perspectives. Angewandte
Chemie International Edition
20. Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584–1600
21. Kudłak B, Wieczerzak M (2020) Aptamer based tools for environmental and therapeutic
monitoring: A review of developments, applications, future perspectives. Critical Reviews in
Environmental Science and Technology 50(8):816–867
22. Hassel S, Mayer G (2019) Aptamers as therapeutic agents: Has the initial Euphoria subsided?
Mol Diagn Therapy 23(3):301–309
M. Irfan et al.
References
1. Vogenberg FR, Barash CI, Pursel M (2010) Personalized medicine: part 1: evolution and
development into theranostics. Pharm Ther 35(10):560
2. Xing H, Hwang K, Li J, Torabi S-F, Lu Y (2014) DNA aptamer technology for personalized
medicine. Curr Opin Chem Eng 4:79–87
3. Tebani A, Abily-Donval L, Afonso C, Marret S, Bekri S (2016) Clinical metabolomics: the
new metabolic window for inborn errors of metabolism investigations in the post-genomic
era. Int J Mol Sci 17(7):1167
4. Wang T, Chen C, Larcher LM, Barrero RA, Veedu RN (2019) Three decades of nucleic acid
aptamer technologies: lessons learned, progress and opportunities on aptamer development.
Biotechnol Adv 37(1):28–50
5. Piffoux M, Nicolás-Boluda A, Mulens-Arias V, Richard S, Rahmi G, Gazeau F, Wilhelm
C, Silva AK (2019) Extracellular vesicles for personalized medicine: the input of physically
triggered production, loading and theranostic properties. Adv Drug Deliv Rev 138:247–258
6. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific
ligands. Nature 346 (6287):818–822
7. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA
ligands to bacteriophage T4 DNA polymerase. Science 249 (4968):505–510
8. Xing H, Wong NY, Xiang Y, Lu Y (2012) DNA aptamer functionalized nanomaterials for
intracellular analysis, cancer cell imaging and drug delivery. Curr Opin Chem Biol 16(3–
4):429
9. Beaudry AA, Joyce GF (1992) Directed evolution of an RNA enzyme. Science
257(5070):635–641
10. Willner I, Zayats M (2007) Electronic Aptamer-Based Sensors. AngewandteChemie International Edition 46(34):6408–6418
11. Cai S, Yan J, Xiong H, Liu Y, Peng D, Liu Z (2018) Investigations on the interface of nucleic
acid aptamers and binding targets. Analyst 143(22):5317–5338
12. Tao X, Huang Y, Wang C, Chen F, Yang L, Ling L, Che Z, Chen X (2020) Recent developments
in molecular docking technology applied in food science: a review. Int J Food Sci Technol
21(7):33–45
13. Yadav B, Sellamuthu B, Tyagi R (2020) Riboswitches and aptamers: potential future targets to
control drug-resistant bacteria. Current Developments in Biotechnology and Bioengineering:
Environmental and Health Impact of Hospital Wastewater, pp 421–462
14. Xiang D, Zheng C, Zhou S-F, Qiao S, Tran PH-L, Pu C, Li Y, Kong L, Kouzani AZ, Lin J
(2015) Superior performance of aptamer in tumor penetration over antibody: implication of
aptamer-based theranostics in solid tumors. Theranostics 5(10):1083
15. Urak KT (2018) Detection and treatment of critical illnesses using oligonucleotides
16. Wang RE, Wu H, Niu Y, Cai J (2011) Improving the stability of aptamers by chemical
modification. Curr Med Chem 18(27):4126–4138
17. Dunn MR, Jimenez RM, Chaput JC (2017) Analysis of aptamer discovery and technology.
Nat Rev Chem 1(10):1–16
18. Sun H, Zu Y (2015) A highlight of recent advances in aptamer technology and its application.
Molecules 20(7):11959–11980
19. Tan W, Li L, Xu S, Yan H, Li X, Yazd HS, Li X, Huang T, Cui C, Jiang J (2020) Nucleic acid
aptamers for molecular diagnostics and therapeutics: advances and perspectives. Angewandte
Chemie International Edition
20. Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46(4):1584–1600
21. Kudłak B, Wieczerzak M (2020) Aptamer based tools for environmental and therapeutic
monitoring: A review of developments, applications, future perspectives. Critical Reviews in
Environmental Science and Technology 50(8):816–867
22. Hassel S, Mayer G (2019) Aptamers as therapeutic agents: Has the initial Euphoria subsided?
Mol Diagn Therapy 23(3):301–309